Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
1.200
+0.040 (3.45%)
At close: Mar 17, 2026, 4:00 PM EDT
1.250
+0.050 (4.17%)
After-hours: Mar 17, 2026, 7:57 PM EDT
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
90
Market Cap
156.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vaxart | 237.26M |
| Heron Therapeutics | 154.90M |
| Karyopharm Therapeutics | 146.07M |
| Agenus | 114.20M |
| Evaxion | 7.53M |
| Molecular Partners AG | 856.30K |
| Connect Biopharma Holdings | 762.00K |
| Artiva Biotherapeutics | 251.00K |
IMUX News
- 7 days ago - Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium - PRNewsWire
- 14 days ago - Immunic to Participate in Investor Conferences in March - PRNewsWire
- 19 days ago - Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 4 weeks ago - Immunic Announces Closing of Oversubscribed Private Placement Financing - PRNewsWire
- 4 weeks ago - Immunic Stock Jumps After Pricing $400 Million Private Placement - Benzinga
- 4 weeks ago - Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company - PRNewsWire
- 5 weeks ago - Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis - PRNewsWire
- 2 months ago - Immunic Highlights 2025 Accomplishments and Upcoming Milestones - PRNewsWire